Yuki Okada from 100 Rock Haven Rd, Carrboro, NC 27510, Phone: 919 942-9059

About:

Born:

04 October 1983 • Fujieda, Shizuoka , Japan

Work:

Yuki Okada is a Japanese people football ( soccer ) player who currently plays for Japan Football League club Fujieda MYFC.

Skills & Activities:

Sport:

Japanese football player • J. League Division 2 player • Consadole Sapporo player • Tochigi SC player • Mito HollyHock player • Football • Club

Diagnostic And Therapeutic Targets For Leukemia
view source
US Patent:

8524467, Sep 3, 2013
Filed:

Dec 6, 2006
Appl. No.:

12/161482
Inventors:

Yi Zhang - Chapel Hill NC, US
Yuki Okada - Carrboro NC, US
Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:

C12Q 1/68
G01N 33/00
G01N 33/53
G01N 33/542
G01N 33/567
G01N 33/574
US Classification:

435 79, 435 4, 435 721, 435 723, 435 724, 435 76, 435 772
Abstract:

The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity.

Dot1 Histone Methyltransferases As A Target For Identifying Therapeutic Agents For Leukemia
view source
US Patent:

20050048634, Mar 3, 2005
Filed:

Jun 14, 2004
Appl. No.:

10/866908
Inventors:

Yi Zhang - Chapel Hill NC, US
Qin Feng - Houston TX, US
Yuki Okada - Carrboro NC, US
Guoliang Xu - Shanghai, CN
International Classification:

C12Q001/68
C07H021/04
C12N009/10
US Classification:

435193000, 435069100, 435320100, 435325000, 536023200, 435006000
Abstract:

The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Dot1 Histone Methyltransferases As A Target For Identifying Therapeutic Agents For Leukemia
view source
US Patent:

20090269751, Oct 29, 2009
Filed:

Oct 14, 2008
Appl. No.:

12/251037
Inventors:

YI ZHANG - CHAPEL HILL NC, US
QIN FENG - HOUSTON TX, US
YUKI OKADA - CARRBORO NC, US
GUOLIANG XU - SHANGHAI, CN
International Classification:

C12Q 1/68
C07H 21/04
C12N 15/63
C12N 5/10
C12P 21/02
G01N 33/53
US Classification:

435 6, 536 235, 4353201, 435325, 435 691, 435 71
Abstract:

The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Dot1 Histone Methyltransferases As A Target For Identifying Therapeutic Agents For Leukemia
view source
US Patent:

20100151453, Jun 17, 2010
Filed:

Oct 14, 2008
Appl. No.:

12/251078
Inventors:

YI ZHANG - CHAPEL HILL NC, US
QIN FENG - HOUSTON TX, US
YUKI OKADA - CARRBORO NC, US
GUOLIANG XU - SHANGHAI, CN
International Classification:

C12Q 1/48
C07H 21/04
G01N 33/53
C12Q 1/68
US Classification:

435 6, 536 2374, 435 15, 435 71
Abstract:

The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Deficiency In The Histone Demethylase Jhdm2A Results In Impaired Energy Expenditure And Obesity
view source
US Patent:

20110138488, Jun 9, 2011
Filed:

Jun 23, 2009
Appl. No.:

12/999059
Inventors:

Yi Zhang - Chapel Hill NC, US
Yuki Okada - Carrboro NC, US
Keisuke Tatelshi - Tokyo, JP
International Classification:

G01N 33/00
A01K 67/00
C12N 5/10
C12Q 1/02
C12Q 1/68
US Classification:

800 3, 800 9, 435354, 435 29, 435 611
Abstract:

The present invention relates to animal models of metabolic disorders such as obesity, diabetes, metabolic syndrome, insulin resistance, hyperinsulinemia, glucose intolerance, hyperlipidemia, and the like. In particular, the invention relates to transgenic non-human animals having a reduction in functional Jhdm2a gene expression and use of such animals and cells having reduced Jhdm2a expression in drug discovery. The invention further relates to the identification of subjects having or at increased risk for developing a metabolic disorder based on a genetic marker in the Jhdm2a gene.